Vis enkel innførsel

dc.contributor.authorKjelby, Eirik
dc.contributor.authorGjestad, Rolf
dc.contributor.authorFathian, Farivar
dc.contributor.authorSinkeviciute, Igne
dc.contributor.authorAlisauskiene, Renata
dc.contributor.authorAnda, Liss
dc.contributor.authorLøberg, Else-Marie
dc.contributor.authorReitan, Solveig Klæbo
dc.contributor.authorJoa, Inge
dc.contributor.authorLarsen, Tor Kjetil
dc.contributor.authorRettenbacher, Maria
dc.contributor.authorBerle, Jan Øystein
dc.contributor.authorFasmer, Ole Bernt
dc.contributor.authorKroken, Rune Andreas
dc.contributor.authorJohnsen, Erik
dc.description.abstractBackground Depressive symptoms are frequent in schizophrenia and associated with a poorer outcome. Currently, the optimal treatment for depressive symptoms in schizophrenia remains undetermined. Amisulpride, aripiprazole, and olanzapine all have antidepressive pharmacodynamic properties, ranging from serotonergic affinities to limbic dopaminergic selectivity. Consequently, in a 12-month pragmatic, randomized clinical trial, we aimed to investigate differences in antidepressive effectiveness among amisulpride, aripiprazole, and olanzapine as a secondary outcome, measured by change in the Calgary Depression Scale for Schizophrenia sum score in patients within the schizophrenia spectrum. Methods Psychotic patients within the schizophrenia spectrum were included, and effectiveness was analyzed with latent growth curve modeling. Results Of the 144 patients, 51 (35%) were women, the mean age was 31.7 (SD 12.7), and 39% were antipsychotic naive. At inclusion, 68 (47%) participants had a Calgary Depression Scale for Schizophrenia sum score >6, indicating severe depressive symptoms. Across the 12-month follow-up, there was a depressive symptom reduction in all medication groups, but no statistically significant differences between the study drugs. Separate analyses of the subcohort with elevated depressive symptoms at inclusion also failed to find differences in depressive symptom reduction between study drugs. The reduction in depressive symptoms mainly occurred within 6 weeks after randomization. Conclusions There was a reduction in depressive symptoms under treatment with amisulpride, aripiprazole, and olanzapine in acutely psychotic patients with schizophrenia spectrum disorder, but no differences between the drugs.en_US
dc.publisherWolters Kluweren_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.titleAntidepressive Effectiveness of Amisulpride, Aripiprazole, and Olanzapine in Patients with Schizophrenia Spectrum Disorders: A Secondary Outcome Analysis of a Pragmatic, Randomized Trial (BeSt InTro)en_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.rights.holderCopyright 2023 The Author(s)en_US
dc.source.journalJournal of Clinical Psychopharmacologyen_US
dc.identifier.citationJournal of Clinical Psychopharmacology. 2023, 43 (3), 246-258.en_US

Tilhørende fil(er)


Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal